These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16272751)

  • 1. Pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra short-acting beta1-selective blocker, in a dose escalation regimen in healthy male volunteers.
    Murakami M; Furuie H; Matsuguma K; Wanibuchi A; Kikawa S; Irie S
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):337-44. PubMed ID: 16272751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects.
    Wang M; Zhang Q; Hua W; Zhou W; Huang M; Wang H
    Drug Res (Stuttg); 2014 Mar; 64(3):141-5. PubMed ID: 24002929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.
    Taenaka N; Kikawa S
    Am J Cardiovasc Drugs; 2013 Oct; 13(5):353-64. PubMed ID: 23818039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker.
    Takahata T; Yasui-Furukori N; Sakamoto J; Suto K; Suto T; Tateishi T; Munakata A
    Drugs R D; 2005; 6(6):385-94. PubMed ID: 16274261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.
    Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
    Eur J Clin Pharmacol; 2017 Apr; 73(4):417-428. PubMed ID: 28091703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, phase III study of the short-acting β1-adrenergic receptor blocker landiolol hydrochloride for coronary computed tomography angiography in Japanese patients with suspected ischemic cardiac disease.
    Hirano M; Yamashina A; Hara K; Ikari Y; Jinzaki M; Iino M; Yamaguchi T; Tanimoto M; Kuribayashi S;
    Clin Drug Investig; 2014 Jan; 34(1):53-62. PubMed ID: 24174275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J
    BMC Pharmacol Toxicol; 2020 Nov; 21(1):82. PubMed ID: 33239108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.
    Krumpl G; Ulc I; Trebs M; Kadlecová P; Hodisch J
    Eur J Pharm Sci; 2016 Sep; 92():64-73. PubMed ID: 27373605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
    J Cardiovasc Pharmacol; 2018 Mar; 71(3):137-146. PubMed ID: 29112591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias.
    Atarashi H; Kuruma A; Yashima M; Saitoh H; Ino T; Endoh Y; Hayakawa H
    Clin Pharmacol Ther; 2000 Aug; 68(2):143-50. PubMed ID: 10976545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia.
    Mizuno J; Yoshiya I; Yokoyama T; Yamada Y; Arita H; Hanaoka K
    Eur J Clin Pharmacol; 2007 Mar; 63(3):243-52. PubMed ID: 17211618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites.
    Krumpl G; Ulč I; Trebs M; Kadlecová P; Hodisch J; Maurer G; Husch B
    J Cardiovasc Pharmacol; 2017 Jul; 70(1):42-51. PubMed ID: 28437278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients.
    Kunisawa T; Yamagishi A; Suno M; Nakade S; Higashi R; Kurosawa A; Sugawara A; Matsubara K; Iwasaki H
    J Anesth; 2015 Apr; 29(2):198-205. PubMed ID: 25186494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bolus administration of landiolol, a short-acting, selective beta1-blocker, to treat tachycardia during anesthesia: a dose-dependent study.
    Harasawa R; Hayashi Y; Iwasaki M; Kamibayashi T; Mashimo T
    J Cardiothorac Vasc Anesth; 2006 Dec; 20(6):793-5. PubMed ID: 17138082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landiolol attenuates the cardiovascular response to tracheal intubation.
    Goyagi T; Tanaka M; Nishikawa T
    J Anesth; 2005; 19(4):282-6. PubMed ID: 16261464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
    Jinzaki M; Hirano M; Hara K; Suzuki T; Yamashina A; Ikari Y; Iino M; Yamaguchi T; Kuribayashi S
    Int J Cardiovasc Imaging; 2013 Jun; 29 Suppl 1(Suppl 1):7-20. PubMed ID: 23784548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of landiolol for suppressing the hyperdynamic response following laryngoscopy and tracheal intubation: a systematic review.
    Inoue S; Tanaka Y; Kawaguchi M; Furuya H
    Anaesth Intensive Care; 2009 Nov; 37(6):893-902. PubMed ID: 20014594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischemic cardiac disease.
    Hirano M; Yamashina A; Hara K; Ikari Y; Jinzaki M; Iino M; Yamaguchi T; Tanimoto M; Kuribayashi S;
    Drugs R D; 2014 Sep; 14(3):185-94. PubMed ID: 25091378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan.
    Hirano M; Hara K; Ikari Y; Jinzaki M; Iino M; Hamada C; Kuribayashi S
    Adv Ther; 2013 Sep; 30(9):803-18. PubMed ID: 24062147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of landiolol hydrochloride on cardiohemodynamics in patients who underwent coronary artery bypass grafting].
    Iwasawa K; Nakagawa H; Katou M; Yonezawa K; Nishizawa M; Yanagiya N
    Masui; 2005 Apr; 54(4):402-7. PubMed ID: 15852628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.